Cargando…

Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer

Approximately 25% of patients with ovarian cancer harbor a pathogenic BRCA1/2 mutation that has been associated with favorable responses for targeted therapy with poly (ADP-ribose) polymerase 1 (PARP1) inhibitors compared to wild-type individuals. The overall frequency of germline and somatic BRCA1/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ratajska, Magdalena, Koczkowska, Magdalena, Żuk, Monika, Gorczyński, Adam, Kuźniacka, Alina, Stukan, Maciej, Biernat, Wojciech, Limon, Janusz, Wasąg, Bartosz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731877/ https://www.ncbi.nlm.nih.gov/pubmed/29254167 http://dx.doi.org/10.18632/oncotarget.20722

Ejemplares similares

Detection of somatic BRCA1/2 mutations in ovarian cancer – next‐generation sequencing analysis of 100 cases
por: Koczkowska, Magdalena, et al.
Publicado: (2016)

Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing
por: Ratajska, Magdalena, et al.
Publicado: (2014)

Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients
por: Koczkowska, Magdalena, et al.
Publicado: (2018)

Bayesian multilevel model of micro RNA levels in ovarian-cancer and healthy subjects
por: Wiczling, Paweł, et al.
Publicado: (2019)

Spectrum of NIPBL gene mutations in Polish patients with Cornelia de Lange syndrome
por: Kuzniacka, Alina, et al.
Publicado: (2012)

Erratum to: Spectrum of NIPBL gene mutations in Polish patients with Cornelia de Lange syndrome
por: Kuzniacka, Alina, et al.
Publicado: (2013)

Analysis of large mutations in BARD1 in patients with breast and/or ovarian cancer: the Polish population as an example
por: Klonowska, Katarzyna, et al.
Publicado: (2015)

Cancer predisposing BARD1 mutations in breast-ovarian cancer families
por: Ratajska, Magdalena, et al.
Publicado: (2012)

HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours
por: Brożek, Izabela, et al.
Publicado: (2006)

Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer’s disease
por: Jasiecki, Jacek, et al.
Publicado: (2019)

Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases
por: Brozek, Izabela, et al.
Publicado: (2012)

BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer
por: Pilyugin, Maxim, et al.
Publicado: (2021)

New Approach to Paediatric Mastocytosis: Implications of KIT D816V Mutation Detection in Peripheral Blood
por: CZARNY, Justyna, et al.
Publicado: (2020)

Antagonizing functions of BARD1 and its alternatively spliced variant BARD1δ in telomere stability
por: Pilyugin, Maxim, et al.
Publicado: (2016)

Prevalence of the most frequent BRCA1 mutations in Polish population
por: Brozek, Izabela, et al.
Publicado: (2011)

Application of high-resolution genomic profiling in the differential diagnosis of liposarcoma
por: Koczkowska, Magdalena, et al.
Publicado: (2017)

Mosaic Intronic NIPBL Variant in a Family With Cornelia de Lange Syndrome
por: Krawczynska, Natalia, et al.
Publicado: (2018)

Impact of Activation of EGFL7 within Microenvironment of High Grade Ovarian Serous Carcinoma on Infiltration of CD4+ and CD8+ Lymphocytes
por: Sznurkowski, Jacek J., et al.
Publicado: (2022)

The algorithm for Alzheimer risk assessment based on APOE promoter polymorphisms
por: Limon-Sztencel, Anna, et al.
Publicado: (2016)

Novel Tools for Comprehensive Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants
por: Jasiecki, Jacek, et al.
Publicado: (2023)

BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases
por: Suszynska, Malwina, et al.
Publicado: (2020)

The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease’s phenotype
por: Sobieralski, Patryk, et al.
Publicado: (2023)

MAML2 rearrangement as a useful diagnostic marker discriminating between Warthin tumour and Warthin-like mucoepidermoid carcinoma
por: Bieńkowski, Michał, et al.
Publicado: (2020)

An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number
por: Szutowicz-Zielinska, Ewa, et al.
Publicado: (2016)

Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland
por: Jasiewicz, Andrzej, et al.
Publicado: (2022)

MLH1 promoter hypermethylation in uterine carcinosarcoma rarely coexists with TP53 mutation
por: Kunc, Michal, et al.
Publicado: (2019)

New Insights into Butyrylcholinesterase Activity Assay: Serum Dilution Factor as a Crucial Parameter
por: Jońca, Joanna, et al.
Publicado: (2015)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
por: Manchana, Tarinee, et al.
Publicado: (2020)

The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status
por: C.E, Drechsel Katja, et al.
Publicado: (2022)

PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland
por: Kluska, Anna, et al.
Publicado: (2017)

Genomic findings in patients with clinical suspicion of 22q11.2 deletion syndrome
por: Koczkowska, Magdalena, et al.
Publicado: (2016)

On the significance of germline cytogenetic rearrangements at MYCN locus in neuroblastoma
por: Lipska, Beata S, et al.
Publicado: (2013)

Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
por: Birkbak, Nicolai Juul, et al.
Publicado: (2013)

BRCA mutations in the manifestation and treatment of ovarian cancer
por: Pan, Zimin, et al.
Publicado: (2017)

Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
por: Arakelyan, Arsen, et al.
Publicado: (2021)

Intrasalivary Thymic Carcinoma: A Case Report and Literature Review
por: Kunc, Michał, et al.
Publicado: (2021)

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_p4ll2208p2jnnnd648ptab61mt